Effect of Olive leaves extract on the antidiabetic effect of glyburide for possible herb-drug interaction

Publication date: Available online 11 October 2019Source: Saudi Pharmaceutical JournalAuthor(s): Maged S. Abdel-Kader, Gamal A. Soliman, Rehab F. Abdel-Rahman, Abdulaziz S. Saeedan, Reham M. Abd-Elsalam, Hanan A. OgalyAbstractThe concomitant use of olive leaves (OL) and glyburide (GLB) is a possible therapy for diabetic patients. However, there is no report about the effect of OL on the antidiabetic effect of GLB till now. In the current study, the possible interaction of olive leaves extract (OLE) with GLB was assessed to determine if there was any pharmacological benefit over GLB alone. Seven groups of male Sprague Dawley rats were used. Normal rats of the 1st group treated with 2 mL/kg of 3% Tween 80 (vehicle). The 2nd-5th groups were diabetic rats received vehicle, GLB (5 mg/kg), OLE low dose and OLE high dose respectively, while the 6th-7th groups administered combinations of GLB plus OLE low dose and GLB plus OLE high dose, respectively. All treatments were administered orally once daily for 8 weeks.The use of GLB+OLE-500 obviously improved fasting blood glucose (FBG), insulin and glycated hemoglobin (HbA1c) in diabetic rats (95.5±5.55 mg/dL, 6.8±0.16 mg/dL and 6.1±0.29%, respectively) compared to those treated with GLB monotherapy (140.0±6.36 mg/dL, 5.4±0.19 mg/dL and 7.0±0.20%, respectively). The lipid profile [triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein ...
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research

Related Links:

In this report, we did a post-hoc analysis of cardiovascular and renal outcomes over 10 years following randomisation, including a 5 years post-intervention follow-up. As in the original trial, the primary endpoint was a composite of first cardiovascular event, including cardiovascular mortality, cardiovascular morbidity (non-fatal myocardial infarction and non-fatal stroke), revascularisation, and non-traumatic amputation, up to Dec 31, 2014. Analyses were based on the intention-to-treat principle. ADDITION-Europe is registered with ClinicalTrials.gov, NCT00237549.Findings343 general practices were randomly assigned to ro...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
Authors: Babinska A, Kaszubowski M, Kmieć P, Sworczak K Abstract BACKGROUND: Adipose tissue secretes many adipokines and cytokines, which may be an additional risk factor of cardiovascular and metabolic diseases in patients with an incidentally discovered pheochromocytoma (PHEO). The aim of the study was to investigate levels of selected adipocytokines in these patients. METHODS: This prospective study included 12 patients with an incidentally discovered PHEO and 18 healthy participants. In all participants plasma/serum concentrations of triglycerides, HDL and LDL cholesterol, insulin, glucose, adipocytokines ...
Source: Minerva Endocrinologica - Category: Endocrinology Tags: Minerva Endocrinol Source Type: research
Background: The development of strategies that could not only efficiently detect the onset of Amyotrophic Lateral Sclerosis (ALS), a fatal neurodegenerative disorder with no cure but also predict its development and evaluate therapeutic intervention would be of great value. In this respect, the metabolic status of ALS patients has called attention. Hence, this study aimed to investigate the potential correlation between changes in ALS's metabolic parameters with the disease outcome in a systematic review.Methods: The manuscripts were manually searched within different databases (PubMed, Web of Science and Cochrane). The in...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Publication date: Available online 18 November 2019Source: Saudi Journal of Biological SciencesAuthor(s): V. Duraipandiyan, R. Balamurugan, Naif Abdullah Al-Dhabi, T. William Raja, P. Ganesan, B. Ahilan, M. Valan Arasu, S. Ignacimuthu, Galal Ali EsmailAbstractBorassus flabellifer L. is a tall palm traditionally used for its stimulating, diuretic and anti-inflammatory activities; it is rich in fibers and various pharmacologically important secondary metabolites. The present study was undertaken to evaluate the antidiabetic effects of Borassus flabellifer fruit methanol extract (BF-M) on diabetic rats induced with High Fat D...
Source: Saudi Journal of Biological Sciences - Category: Biology Source Type: research
After a stroke, the main goal is to get back home and be as independent as possible. To achieve that goal, most stroke rehabilitation centers focus on helping people to regain lost function, such as the inability to use a hand, to speak, to swallow, or to walk. A great deal of effort is put into functional recovery so that the patient can go home safely and adequately perform activities of daily living (ADLs). There is little effort put into aerobic exercise and conditioning in most stroke rehabilitation programs. A recent systematic review and meta-analysis published in the Journal of the American Heart Association (JAHA)...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Exercise and Fitness Hypertension and Stroke Source Type: blogs
AbstractPurpose of ReviewThis review intends to highlight selected cardiovascular disease (CVD) prevention studies presented at the 2019 European Society of Cardiology (ESC) Congress.Recent FindingsResults from the Inclisiran for Subjects with ASCVD or ASCVD-risk Equivalent and Elevated Low-density Lipoprotein Cholesterol (ORION-11) trial validate inclisiran ’s ability to significantly lower low-density lipoprotein cholesterol (LDL-C) levels in at-risk individuals on a background of maximally tolerated statin therapy. The EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndrom...
Source: Current Atherosclerosis Reports - Category: Cardiology Source Type: research
The association between statins and diabetes mellitus (DM) remains controversial. The Kaiser Permanente CHAMP Study identified adults without DM who had CV risk factors and no prior lipid lowering therapy (LLT) between 2008 and 2010. The CV risk factors included known atherosclerotic CV disease (ASCVD), elevated low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL, or an LDL-C between 70-189 mg/dL and an estimated 10-year ASCVD risk ≥7.5%. Incident DM was defined as ≥2 abnormal tests (i.e., A1C ≥6.5% or a fasting blood glucose ≥126 mg/dL) or ≥1 abnormal test result plus a new diagnostic code or medication for DM.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Conclusions: The higher prevalence of elevated FG and/or T2DM among Roma does not seem to be directly linked to their increased genetic load but rather to their environmental/cultural attributes. Interventions targeting T2DM prevention among Roma should focus on harmful environmental exposures related to their unhealthy lifestyle.
Source: Genes - Category: Genetics & Stem Cells Authors: Tags: Article Source Type: research
AbstractPurposeEra Disruption 4.0 demands development in the management of Diabetes Mellitus (DM) by using application-based intervention that can facilitate nursing intervention. The aim was to evaluate the effect of diabetes mellitus calendar app as a Diabetes Self-Management Education (DSME) program on self-efficacy, HbA1c levels, lipid profile, and insulin in adult type 2 diabetes mellitus (T2DM).MethodsIt was randomized experimental design — simple random sampling used with a total sample of 30 respondents. The instruments used diabetes management self-efficacy scales and standard of operational procedure blood ...
Source: Journal of Diabetes and Metabolic Disorders - Category: Endocrinology Source Type: research
A firm that was labeled one of Medtech’s 16 Most Promising Private Companies by Canaccord Genuity earlier this year, has strong results from a study that will help with FDA approval. LimFlow recently announced positive six-month data from the full patient cohort in its PROMISE I early feasibility study of the Percutaneous Deep Vein Arterialization (pDVA) System. The Paris-based company presented the data during the Vascular Interventional Advances [VIVA] Conference held in Las Vegas, earlier this month. The company’s technology is used for the treatment of chronic limb-threatening ischem...
Source: MDDI - Category: Medical Devices Authors: Tags: Cardiovascular Source Type: news
More News: Antidoxidants | Cholesterol | Diabetes | Drugs & Pharmacology | Endocrinology | Genetics | Glyburide | Herbs | Insulin | Liver | Middle East Health | Pancreas | Saudi Arabia Health | Study | Urology & Nephrology